The main conclusion drawn from the study is that ION-ZC1 Topical Cream (17%) is:
(i) Significantly efficacious against metastatic mouse melanoma as tested in a subcutaneous syngeneic mouse model (B16-F0 in C57BL/6J mice).
(ii) More efficacious than the Imiquimod Topical Cream (5%).
(iii) Tumor volumes recorded over the treatment period in the three groups support that tumor growth was slower as inhibited by ION-ZC1 Topical Cream (17%), and its effect was more pronounced as compared to the inhibitory effect of ALDARA (5% Imiquimod) Positive Control substance on tumor growth.
(iv) Conclusively, ION-ZC1 Topical Cream (17%) treatment extended survival time.
Completed in 2017 by the University of Debrecen, Hungary.
